Approval · Notice of Compliance 30967 · 2023
SUSTIVA: Notice of Compliance 30967
Issued June 9, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30967
- Date
- June 9, 2023
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph (PM) to remove information related to 600 mg tablet due to post-market cancellation
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUSTIVA | Not yet assigned | — |